Benign prostat hiperplazisi olan hastalarda PSA kullanımı

Ali ATAN (Gazi Üniversitesi Tıp Fakültesi, Üroloji Anabilim Dalı, Ankara, Türkiye)
Androloji Bülteni
10 3
Yıl: 2022 Cilt: 24 Sayı: 4 Sayfa Aralığı: 273 - 277 Metin Dili: Türkçe DOI: 10.24898/tandro.2022.93653 İndeks Tarihi: 03-05-2023

Benign prostat hiperplazisi olan hastalarda PSA kullanımı

Öz:
Prostat Spesifik Antijen (PSA), prostat asinilerinden salgılanan bir glikoproteindir. Prostat spesifik antijen sıklıkla prostat kanseri (PKa) için kullanılan bir test olarak düşünülmesine karşın PSA hastalık özel bir belirteç değildir, organ özel bir belirteçtir. Serum PSA düzeyinin kesinlikle prostat kanseri tanısında önemli olduğu kadar prostatın diğer benign durumlarında da önemli olduğu unutulmamalıdır. Bu derleme makalede serum PSA düzeyinin Benign Prostat Hiperplazisi (BPH) tanısında, BPH progresyonunun öngörülmesinde, BPH medikal tedavisini seçiminde ve medikal tedavi altındaki hastaların takibindeki kullanımı anlatılmaktadır.
Anahtar Kelime:

Usage of PSA in patients with benign prostatic hyperplasia

Öz:
Prostate Specific Antigen (PSA) is a glycoprotein secreted from prostate acini. Although PSA is generally considered a test used for prostate cancer (PCa), PSA is an organ-specific marker, not a disease-specific marker. It should not be forgotten that serum PSA level is important in the diagnosis of prostate cancer as well as in other benign conditions of the prostate. In this review article, the use of serum PSA in the diagnosis of BPH, in the prediction of Benign Prostatic Hyperplasia (BPH) progression, in the selection of BPH medical treatment, and in the follow-up of patients under medical treatment is described.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • 1. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol. 1979;17:159–63. https://pubmed.ncbi.nlm.nih.gov/89106/
  • 2. Venderbros LDF, Roobol MJ. PSA-based prostate cancer screening: the role of active surveillance and informed and shared decision making. Asian J Androl. 2011;13:219–24. [CrossRef]
  • 3. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317:909–16. [CrossRef]
  • 4. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324:1156– 61. [CrossRef]
  • 5. Mettlin C, Murhpy GP, Lee F, Littrup PJ, Chesley A, Babaian R, et al. Characteristics of prostate cancers detected in a multimodality early detection program. The Investigators of the American Cancer Society-National Prostate Cancer Detection Project. Cancer. 1993;72:1701–8. [CrossRef]
  • 6. Obort AS, Ajadi MB, Akinloye O. Prostate-specific antigen: any successor in sight? Rev Urol. 2013;15:97–107. https://pubmed. ncbi.nlm.nih.gov/24223021/
  • 7. van Renterghem K, van Koeveringe G, Achten R, van Kerrebroeck P. A new algorithm in patients with elevated and/or rising prostatespecific antigen level, minor lower urinary tract symptoms, and negative multisite prostate biopsies. Int Urol Nephrol. 2010;42:29– 38. [CrossRef]
  • 8. Gjertson CK, Albertsen PC. Use and assessment of PSA in prostate cancer. Med Clin North Am. 2011;95:191–200. [CrossRef]
  • 9. Greene KL, Albertsen PC, Babaian R, Carter HB, Gann PH, Han M, et al. Prostate specific antigen best practice statement:2009 update. J Urol. 2013;189:S2–11. [CrossRef]
  • 10. Oesterling JE, Rice DC, Glenski WJ, Bergstralh EJ. Effect of cystoscopy, prostate biopsy, and transurethral resection of prostate on serum prostate-specific antigen concentration. Urology. 1993;42:276–82. [CrossRef]
  • 11. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level <or =4.0 ng per milliliter. N Engl J Med. 2004;35:2239–46. [CrossRef]
  • 12. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474–9. [CrossRef]
  • 13. Gravas S, Cornu JN, Gacci M, Gratzke C, Herrmann TRW, Mamoulakis C, Rieken M, et al. EAU guidelines on management of non-neurogenic male lower urinary tract symptoms (LUTS) -Update March 2022. https://d56bochluxqnz.cloudfront.net/ documents/full-guideline/EAU-Guidelines-on-Non-NeurogenicMale-LUTS-2022.%20pdf
  • 14. Gao XD, Miao Q, Zhang JL, Zhai JZ, Gui XM, Cai YH, et al. Clinical application of free/total PSA ratio in the diagnosis of prostate cancer in men over 50 years of age with total PSA levels of 2. 0-25. 0 ng ml -1 in Western China. Asian J Androl. 2022;24:195–200. [CrossRef]
  • 15. Liu X, Tang J, Fei X, Li Q-Y. Prostate-specific Antigen (PSA) Density and free to total PSA ratio in diagnosing prostate cancer with prostatespecific antigen levels of 4.0 ng/ml or Less. Iran J Public Health. 2015;44:1466–72. https://pubmed.ncbi.nlm.nih.gov/26744703/
  • 16. Amirrasouli H, Kazerouni F, Sanadizade M, Sanadizade J, Kamalian N, Jalali M, et al. Accurate cut-off point for free to total prostatespecific antigen ratio used to improve differentiation of prostate cancer from benign prostate hyperplasia in Iranian population. Urol J. 2010;7:99–104. https://pubmed.ncbi.nlm.nih.gov/20535696/
  • 17. Thakur V, Singh PP, Talwar M, Mukherjee U. Utility of free/total prostate specific antigen (f/t PSA) ratio in diagnosis of prostate carcinoma. Dis Markers. 2004;19:287–92. [CrossRef]
  • 18. Atan A. BPH’nın Progresyonunu Öngörebilir Miyiz? Endoüroloji Bülteni. 2016;9:18–20. [CrossRef]
  • 19. Crawford ED, Wilson SS, McConnell JD, Slawin KM, Lieber MC, Smith JA, et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol. 2006;175:1422–27. [CrossRef]
  • 20. Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology. 1999;53:581–89. [CrossRef]
  • 21. Djavan B, Waldert M, Ghawidel C, Marberger M. Benign prostatic hyperplasia progression and its impact on treatment. Curr Opin Urol. 2004;14:45–50. [CrossRef]
  • 22. Roehrborn CG, Boyle P, Bergner D, Gray T, Gittelman M, Shown T, et al. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. Urology. 1999;54:662–69. [CrossRef]
  • 23. Roehrborn CG, McConnell JD, Lieber M, Kaplan S, Geller J, Malek GH, et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. Urology. 1999;53:473–80. [CrossRef]
  • 24. Roehrborn CG, McConnell J, Bonilla J, Rosenblatt S, Hudson PB, Malek GH, et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. J Urol. 2000;163:13–20. [CrossRef]
  • 25. Anderson JB, Roehrborn CG, Schalken JA, Emberton M. The progression of benign prostatic hyperplasia: examining the evidence and determining the risk. Eur Urol. 2001;39:390–9. [CrossRef]
  • 26. Mochtar CA, Kiemeney LALM, van Riemsdijk MM, Barnett GS, Laguna MP, Debruyne FMJ, de la Rosette JJMCH. Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia. Eur Urol. 2003;44:695–700. [CrossRef]
  • 27. Bosch JLH, Bohnen AM, Groeneveld FPMJ. Validity of digital rectal examination and serum prostate specific antigen in the estimation of prostate volume in community-based men aged 50 to 78 years: the Krimpen Study. Eur Urol. 2004;46:753–59. [CrossRef]
  • 28. Hedelin H, Johansson N, Ströberg P. Relationship between benign prostatic hyperplasia and lower urinary tract symptoms and correlation between prostate volume and serum prostate-specific antigen in clinical routine. Scan J Urol Nephrol. 2005;39:154–59. [CrossRef]
  • 29. Mochtar CA, Kiemeney LALM, Laguna MP, van Riemsdijk MM, Barnett GS, Debruyne FMJ, de la Rosette JJMCH. Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting. Urology. 2005;65:300–5. [CrossRef]
  • 30. Bohnen AM, Groeneveld FP, Ruud Bosch JLH. Serum prostatespecific antigen as a predictor of prostate volume in the community: the Krimpen study. Eur Urol. 2007;51:1645–52. [CrossRef]
  • 31. Lerner LB, McVary KT, Barry MJ, Bixler BR, Dahm P, Das AK, Gandhi MC, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA GUIDELINE PART I-Initial work-up and medical management. J Urol. 2021;206:806–17. [CrossRef]
  • 32. Roehrborn CG, Kaplan SA, Kraus SR, Wang JT, Bavendam T, Guan Z. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. Urology. 2008;72:1061–7. [CrossRef]
  • 33. Guess HA, Gormley GJ, Stoner E, Oesterling JE. The effect of finasteride on prostate specific antigen: review of available data. J Urol. 1996;155:3–9. [CrossRef]
  • 34. Marks LS, Andriole GL, Fitzpatrick JM, Schulman CC, Roehrborn CG. The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. J Urol. 2006;176:868–74. [CrossRef]
  • 35. Andriole GL, Guess HA, Epstein JI, Wise H, Kadmon D, Crawford ED, et al. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology. 1998;52:195–202. [CrossRef]
  • 36. Andriole GL, Marberger M, Roehrborn CG. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor Dutasteride. J Urol. 2006;175:1657–62. [CrossRef]
  • 37. Thompson IM, Chi C, Ankerist DP, Goodman PJ, Tangen CM, Lippman SM, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst. 2006;98:1128– 33. [CrossRef]
  • 38. Andriole GL, Bostwick H, Brawley OW, Gomella L, Marberger M, Montorsi M, et al. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. J Urol. 2011;185:126– 31. [CrossRef]
  • 39. Guess HA, Heyse JF, Gormley GJ, Stoner E, Oesterling JE. Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia. Results from the North American phase III clinical trial. Urol Clin North Am. 1993;20:627–36. https:// pubmed.ncbi.nlm.nih.gov/7505970/
  • 40. Marberger M, Freedland SJ, Andriole GL, Emberton M, Pettaway C, Montorsi F, et al. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study. BJU Int. 2012;109:1162–69. [CrossRef]
  • 41. Keetch DW, Andriole GL, Ratliff TL, Catalona WJ. Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting. Urology. 1997;50:901–5. [CrossRef]
  • 42. Debruyne F, Barkin J, van Erps P, Reis M, Tammela TL, Roehrborn C; ARIA3001, ARIA3002 and ARIB3003 Study Investigators. Efficacy and safety of long-term treatment with the dual 5 alphareductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol. 2004;46:488–94. [CrossRef]
  • 43. Woo C, Kapoor A. Dutasteride for the treatment of benign prostatic hyperplasia. Expert Opin Pharmacother. 2013;14:1399– 408. [CrossRef]
APA Atan A (2022). Benign prostat hiperplazisi olan hastalarda PSA kullanımı. , 273 - 277. 10.24898/tandro.2022.93653
Chicago Atan Ali Benign prostat hiperplazisi olan hastalarda PSA kullanımı. (2022): 273 - 277. 10.24898/tandro.2022.93653
MLA Atan Ali Benign prostat hiperplazisi olan hastalarda PSA kullanımı. , 2022, ss.273 - 277. 10.24898/tandro.2022.93653
AMA Atan A Benign prostat hiperplazisi olan hastalarda PSA kullanımı. . 2022; 273 - 277. 10.24898/tandro.2022.93653
Vancouver Atan A Benign prostat hiperplazisi olan hastalarda PSA kullanımı. . 2022; 273 - 277. 10.24898/tandro.2022.93653
IEEE Atan A "Benign prostat hiperplazisi olan hastalarda PSA kullanımı." , ss.273 - 277, 2022. 10.24898/tandro.2022.93653
ISNAD Atan, Ali. "Benign prostat hiperplazisi olan hastalarda PSA kullanımı". (2022), 273-277. https://doi.org/10.24898/tandro.2022.93653
APA Atan A (2022). Benign prostat hiperplazisi olan hastalarda PSA kullanımı. Androloji Bülteni, 24(4), 273 - 277. 10.24898/tandro.2022.93653
Chicago Atan Ali Benign prostat hiperplazisi olan hastalarda PSA kullanımı. Androloji Bülteni 24, no.4 (2022): 273 - 277. 10.24898/tandro.2022.93653
MLA Atan Ali Benign prostat hiperplazisi olan hastalarda PSA kullanımı. Androloji Bülteni, vol.24, no.4, 2022, ss.273 - 277. 10.24898/tandro.2022.93653
AMA Atan A Benign prostat hiperplazisi olan hastalarda PSA kullanımı. Androloji Bülteni. 2022; 24(4): 273 - 277. 10.24898/tandro.2022.93653
Vancouver Atan A Benign prostat hiperplazisi olan hastalarda PSA kullanımı. Androloji Bülteni. 2022; 24(4): 273 - 277. 10.24898/tandro.2022.93653
IEEE Atan A "Benign prostat hiperplazisi olan hastalarda PSA kullanımı." Androloji Bülteni, 24, ss.273 - 277, 2022. 10.24898/tandro.2022.93653
ISNAD Atan, Ali. "Benign prostat hiperplazisi olan hastalarda PSA kullanımı". Androloji Bülteni 24/4 (2022), 273-277. https://doi.org/10.24898/tandro.2022.93653
Sayfa Oluşturulma Tarihi
27-04-2024 9:29

İLETİŞİM

TÜBİTAK ULAKBİM TR Dizin

Yüzüncüyıl, İşçi Blokları Mahallesi

Muhsin Yazıcıoğlu Caddesi No:51/C

06530 Çankaya / ANKARA +90 (312) 298 92 00

trdizin@tubitak.gov.tr

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © Tüm Hakları Saklıdır. Gizlilik Politikası Kullanım Şartları